Found: 6
Select item for more details and to access through your institution.
Daratumumab in transfusion‐dependent patients with low or intermediate‐1 risk myelodysplastic syndromes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. E111, doi. 10.1002/ajh.26095
- By:
- Publication type:
- Article
P-155: Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S120, doi. 10.1016/S2152-2650(21)02282-5
- By:
- Publication type:
- Article
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02097-8
- By:
- Publication type:
- Article
MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S421, doi. 10.1016/S2152-2650(21)01945-5
- By:
- Publication type:
- Article
Poster: MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01568-8
- By:
- Publication type:
- Article
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00629-1
- By:
- Publication type:
- Article